Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat effects on bone and neuropsychiatric aspects in ESKD
NCT06917950Phase 2Recruiting
- Sponsor
- Mansoura University
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of roxadustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Mansoura University. Primary endpoint: Change in Lumbar Spine Bone Mineral Density at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
roxadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT06917950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917950.